We have built a team that brings together a unique mix of clinical, scientific, business, and philanthropic expertise.

Our Foundation Advisors guide the Target ALS administration in ensuring that we are following best-in-class scientific approaches in our work, and they keep us closely connected to the latest developments in the field.

The Target ALS Board of Directors sets overall policy and provides guidance to the Foundation’s executive leadership team. To ensure we craft truly ground-breaking strategies to foster collaboration and accelerate drug discovery and development, we have recruited a renowned, passionate group of pioneering academic leaders, pharmaceutical and biotech executives, patients and their family members and visionary philanthropists.

To ensure that Target ALS funds the top ideas in the field in an objective manner, all grant-making decisions are made by an Independent Review Committee (IRC). The IRC is comprised of investigators from industry, academia and non-profit organizations who represent expertise from different but complementary areas of science. To avoid a conflict of interest, members of the IRC are neither allowed to apply for, nor receive funding from Target ALS. The committee is chaired by Robert Miller, Ph.D., George Washington University.